Viloxazine or placebo for preschool children with ADHD
About this title
Read the official source — NCT04781140Researchers are comparing 100mg SPN-812 and placebo to find out how the approaches affect ADHD symptoms in children with ADHD.
Understand this study
What is this study about?
Researchers are comparing 100mg SPN-812 and placebo to find out how the approaches affect ADHD symptoms in children with ADHD.
Who could participate?
Listed age limits: 48 months to 69 months.
What will I do during this study?
After screening for up to four weeks, children are randomly assigned to once-daily SPN-812 or placebo (an inactive comparison treatment) for six weeks. The study lasts up to ten weeks in total.
- Listed locations
- Saraland and 53 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 286
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 48 Months to 69 Months
- Official registry ID
- NCT04781140
- Official title
Show the full official title
A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of SPN-812 in Preschool-Age Children (4 to 5 Years Old) With Attention-Deficit/Hyperactivity Disorder (ADHD)
Recruitment & locations
Saraland · Fayetteville · Little Rock
49 more locations
- Anaheim
- Encino
- Garden Grove
- Imperial
- Long Beach
- Newport Beach
- Centennial
- Clermont
- Coral Gables
- Gainesville
- Jacksonville
- Lakeland
- Miami
- Orange City
- Orlando
- Tamarac
- Virginia Gardens
- Winter Park
- Atlanta
- Decatur
- Savannah
- Evansville
- Bardstown
- Owensboro
- New Orleans
- Prairieville
- Baltimore
- Boston
- Bloomfield Hills
- Flowood
- Las Vegas
- Berlin
- Irvington
- Neptune City
- New York
- Durham
- Cincinnati
- West Chester
- Gresham
- Hershey
- North Charleston
- Summerville
- Memphis
- Bellaire
- Dallas
- Plano
- The Woodlands
- Petersburg
- Richmond
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are comparing 100mg SPN-812 and placebo to find out how the approaches affect ADHD symptoms in children with ADHD.
Who is behind this study?
The study sponsor is Supernus Pharmaceuticals, Inc., a pharmaceutical company.
Does this study involve medication?
Yes. The study involves medication, including 100mg SPN-812 and Placebo.
Who can participate?
Listed age limits: 48 months to 69 months.
Is this study still recruiting?
The registry lists this study as recruiting.
